Evidence map›Paper›PMID 42404180›Full record

ArticleJournal of neurological surgery. Part B, Skull base2026

LINAC-based Stereotactic Radiotherapy for Acromegaly: A Single-center Retrospective Cohort.

Geovanne P Mauro, Leila M Da Róz, Vinicius de Carvalho Gico, Silvio Thiago Pereira Vasconcelos, Eduardo Weltman, Evandro C de Souza, Raquel S Jallad, Malebranche Berardo Carneiro da Cunha Neto, Rosangela C Villar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurological surgery. Part B, Skull base, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Geovanne P MauroDepartment of Radiology and Oncology - Discipline of Radiotherapy, Faculdade de Medicina USP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.ORCID 0000-0002-2050-3110
Leila M Da RózDepartment of Neurology - Discipline of Neurosurgery, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Vinicius de Carvalho GicoDepartment of Radiation Oncology, Instituto do Câncer do Estado de São Paulo (ICESP), Medical School of Sao Paulo University, Sao Paulo, SP, Brazil.
Silvio Thiago Pereira VasconcelosDepartment of Radiology and Oncology - Discipline of Radiotherapy, Faculdade de Medicina USP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Eduardo WeltmanDepartment of Radiology and Oncology - Discipline of Radiotherapy, Faculdade de Medicina USP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Evandro C de SouzaDepartment of Neurology - Discipline of Neurosurgery, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Raquel S JalladNeuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil.
Malebranche Berardo Carneiro da Cunha NetoNeuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil.
Rosangela C VillarDepartment of Radiology and Oncology - Discipline of Radiotherapy, Faculdade de Medicina USP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Most results for stereotactic radiotherapy (SRT) for acromegaly patients come from Gamma-Knife series. We aim to describe outcomes for LINAC-based SRT, as well as compare results for single-dose (SRS) and fractionated (SFRT) treatments. Methods: Single-center retrospective cohort in a tertiary, academic hospital assessed between 2008 and 2024. Results: A total of 48 patients were assessed for outcomes of acromegaly after SRT. Most of them female (62.5%). Mean age was 42.5 years (range 12-73). Median lesion size was 2.1 cm (range 0.2 to 7.2 cm). Among previous deficits, previous hormonal deficits (31.3%) and visual deficits (45.8%) were common. Most patients were diagnosed with pure somatotrophic lesions (87.5%). SRS was done in 16 (33.3%) patients and 32 (66.7%) underwent SFRT. Concurrent octreotide long-acting release (Oct-LAR) (29/60.4%) and cabergoline (20/41.7%) were also common. Median follow-up was 85.3 months (8.2-187.9 months). Tumor control was achieved in 47 (97.9%). Mean progression-free survival (PFS) was 85.3 months (92.4 months for SRS and 81.7 months for SFRT, Conclusion: We described acromegaly patients treated with LINAC SRS and with the current criteria for hormonal cure. THC was longer for SFRT patients, with no statistical differences. Concurrent treatment did not impact outcomes.

Indexed as

pituitary GH hypersecretionradiosurgeryradiotherapystereotactic

Identifiers

PMID42404180
PMCPMC13331660

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.